Mechanisms underlying the immunogenicity of therapeutic proteins: Risk assessment and management strategies

Journal of Interferon and Cytokine Research

Volumn 34, Issue 12, 2014, Pages 923-930

  Kirshner, Susan L ^a  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBODY; IMMUNOGLOBULIN; PROTEIN;

CLINICAL TRIAL (TOPIC); CROSS REACTION; HUMAN; IMMUNOGENICITY; NONHUMAN; REVIEW; RISK ASSESSMENT; RISK MANAGEMENT; RISK REDUCTION; STUDY DESIGN;

EID: 84918548317     PISSN: 10799907     EISSN: 15577465     Source Type: Journal    
DOI: 10.1089/jir.2013.0011     Document Type: Review

References (82)

1. Armstrong JK, Hempel G, Koling S, Chan LS, Fisher T, Meiselman JH, Garratty G. 2007. Antibody against poly(ethylene glycol) adversely affects PEG-asparaginase therapy in acute lymphoblastic leukemia patients. Cancer 110:103-111.
2. Barandun S, Kistler P, Jeunet F, Isliker H. 1962. Intravenous administration of human γ-globulin. Vox Sang 7:157-174.
3. Barbosa MD, Vielmetter J, Chu S, Smith DD, Jaccinto J. 2006. Clinical link between MHA class II haplotype and interferonbeta (IFN-beta) immunogenicity. Clin Immunol 118:42-50.
4. Bardor M, Faveeuw C, Fitchette A-C, Gilbert D, Ludovic G, Trottein F, Fay L, Lerouge P. 2003. Immunoreactivity in mammals of two typical plant glycol-epitopes, core alfa(1,3)- fucose and core xylose. Glycobiology 13:427-434.
5. Basser R, O'Flaherty E, Green M, Edmonds M, Nichol J, Menchaca D, Cohen B, Begley C. 2002. Development of pancytopaenia with neutralizing antibodies to thrombopoietin after multicycle chemotherapy supported by megakaryocyte growth and development factor. Blood 99:2599-2602.
6. Brackmann HH, Lenk H, Scharrer I, Auerswald G, Kreuz W. 1999. German recommendations for immune tolerance therapy in type A haemophiliacs with antibodies. Haemophilia 5:203-206.
7. Brady RO, Murray GJ, Oliver KL, Leitman SF, Sneller MC, Fleisher TA, Barton NW. 1997. Management of neutralizing antibody to ceredase in a patient with type 3 Gaucher disease. Pediatrics 100:E11.
8. Brooks DA, Kakavanos R, Hopwood JJ. 2003. Significance of immune response to enzyme-replacement therapy for patients with lysosomal storage disorder. Trends Mol Med 9:450-453.
9. Bryson CJ, Jones TD, Baker MP. 2010. Prediction of immunogenicity of therapeutic proteins: validity of computational tools. BioDrugs 24:1-8.
10. Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hugchinson M, Kappos L, Miller DH, O'Connor PW, Phillips JT, Polman CH, Radue EW, Rudick RA, Stuart Wh, Lublin FD, Wajgt A, Weinstock-Guttman DR, Lyn F, Panzara MA. 2007. The incidence and significance of anti-natalizumab antibodies. Neurology 69:1391-1403.
11. Cerezyme (imiglucerase) for injection: U.S. Prescribing Information. 2003. Cambridge, MA: Genzyme Corp.
12. CDER. 2009. Draft Guidance for Industry: Assay development for immunogenicity testing of therapeutic proteins. Docket No. FDA-2009-D-0539.
13. CDER. 2013. Draft Guidance for Industry: Immunogenicity assessment for therapeutic protein products. Docket No. FDA- 2013-D-0092.
14. Chi EY, Weickmann J, Carpenter JF, Manning MC, Randolph TW. 2005. Heterogeneous nucleation-controlled particulate formation of recombinant human platelet-activatin factor acetylhydrolase in pharmaceutical formulation. J Pharm Sci 94:256-274.
15. Chung CH, Mirakhur B, Chan E, Le Q-T, Berlin J, Morse M, Murphy BA, Satinover SM, Hosen J, Mauro D, Slebos RJ, Zhou Q, Gold D, Hatley T, Hicklin DJ, Platts-Mills TAE. 2008. Cetuximab-induced anaphylaxis and IgE specific for galactose-a-1,3-galactose. N Engl J Med 358:1109-1117.
16. Cox S, Tait R. 1998. Safety, reliability and risk management, 2nd ed. Taylor and Francis. p 6. Online version available at http://app.knovel.com/hotlink/toc/id: KPSRRMA1A1/safetyreliability-risk
17. De Groot AS, Scott DW. 2007. Immunogenicity of protein therapeutics. Trends Immunol 28:482-490.
18. Elelyso (taliglucerase alfa) for injection: U.S. Prescribing Information. 2012. New York, NY: Pfizer Labs.
19. Ellis EF, Henney CS. 1969. Adverse reactions following administration of human gamma globulin. J Allergy 43:45-54.
20. European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). 2008. Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins. www.ema.europa.eu/docs/en-GB/document-library/scientific-guideline/2009/09/WC500003946.pdf
21. European Medicines Agency: Committee for Medicinal Products for Human Use (CHMP). 2012. Guideline on immunogenicity assessment of monoclonal antibodies intended for in vivo clinical use. www.ema.europa.eu/docs/en-GB/document-library/Other/2012/06/WC500128689.pdf
22. Fakharzadeh SS, Kazazian HH Jr. 2000. Correlation between Factor VIII genotype and inhibitor development in hemophilia A. Semin Thromb Hemost 26:167-171.
23. Filipe V, Hawe A, Schellekens H, Jiskoot W. 2010. Aggregation and immunogenicity of therapeutic proteins. In: Wang W, Roberts CJ, eds. Aggregation of therapeutic proteins. Hoboken, NJ: John Wiley and Sons, Inc. pp 403-428.
24. Foss FM, Bacha P, Osann KE, Demierre MV, Bell T, Kuzel T. 2001. Biological correlates of acute hypersensitivity events with DAB(389)IL-2 (denileukin diftitox, ONTAK) in cutaneous T-cell lymphoma: decreased frequency and severity with steroid premedication. Clin Lymphoma 1:298-302.
25. Fotiou F, Aravind S, Wang P-P, Nerapusee O. 2009. Impact of illegal trade on the quality of epoetin alfa in Thailand. Clin Ther 31:336-346.
26. Garay RP, El-Gewely R, Armstrong JK, Garratty G, Richette P. 2012. Antibodies against polyethylene glycol in healthy subjects and in patients treated with PEG-conjugated agents. Expert Opin Drug Deliv 9:1319-1323.
27. Gershon SK, Luksenburg H, Cote TR, Braun MM. 2002. Pure red-cell aplaisia and recombinant erythropoietin. N Engl J Med 346:469-475.
28. Gheuens S, Smith DR, Wang X, Alsop DC, Lenkinski RE, Kiralnik IJ. 2012. Simultaneous PML-IRIS after discontinuation of natalizumab in a patient with MS. Neurology 78:1390-1393.
29. Green RS, Stone EL, Tenno M, Lehtonen E, Farquhar MG, Marth JD. 2007. Mammalian N-glycan branching protects against innate immune self-recognition and inflammation in autoimmune disease pathogenesis. Immunity 27:308-320.
30. Gupta S, Devanarayan V, Finco D, Gunn GR 3rd, Kirshner S, Richards S, Rup B, Song A, Subramanyam M. 2011. Recommendations for the validation of cell-based assays used for the detection of neutralizing antibody immune responses elicited against biological therapeutics. J Pharm Biomed Anal 55:878-888.
31. Gupta S, Indelicato SR, Jethwa V, Kawabata T, Kelley M, Mire-Sluis AR, Richards SM, Rup B, Shores E, Swanson SJ, Wakshull E. 2007. Recommendations for the design, optimization and qualification of cell-based assays used for the detection of neutralizing antibody responses elicited to biological therapeutics. J Immunol Methods 321:1-18.
32. Hamilton RG, Adkinson F, Baltrukonis D, Cullen C, Emrich T, Geng D, Halsey FJ, Homburger HA, Hovanec-Burns DL, Kirshner SL, Matsson PNJ, Moxness M, Wakshull E, Xu Y. 2011. Design and validation of immunoassays for assessment of human allergenicity of new biotherapeutic drugs. Clinical Laboratory Standards Institute 30:1-55.
33. Hay CR, Baglin TP, Collins PW, Hill FG, Keeling DM. 2000. The diagnosis and management of factor VIII and IX inhibitors: a guideline from the UK Haemophilia Centre Doctors' Organization (UKHCDO). Br J Haematol 111:78-90.
34. Hayakawa T, Ishii-Watabe A. 2011. Japanese regulatory perspective on immunogenicity. In: Tovey MG, ed. Detection and quantification of antibodies to biopharmaceuticals: Practical and applied considerations. Hoboken, NJ: John Wiley and Sons, Inc. pp 57-80.
35. Jiang Y, Nashed-Samuel Y, Li C, Liu W, Pollastrini J, Mallard D, Wen AZ, Fujimori K, Pallitto M, Donahue L, Chu G, Torraca G, Vance A, Mire-Sluis T, Freund E, Davis J, Narhi L. 2009. Tungsten-induced protein aggregation: solution behavior. J Pharm Sci 98:4695-4710.
36. Kirshner S. 2011. Immunogenicity of therapeutic proteins: a regulatory perspective. In: Tovey MG, ed. Detection and quantification of antibodies to biopharmaceuticals: Practical and applied considerations. Hoboken, NJ: John Wiley and Sons, Inc. pp 15-37.
37. Kishnani PS, Goldenberg PC, De Armey SL, Heller J, Benjamin D, Young S, Bali D, Smith SA, Li JS, Mandel H, Koeberl D, Rosenberg A, Chen Y-T. 2010. Cross-reactive immunologic material status affects treatment outcomes in Pompe disease infants. Mol Genet Metab 99:26-33.
38. Koren E, Foehr E, O'Niell CA. 2011. Principles of risk assessment and monitoring or antibody responses to biopharmaceuticals. In: Tovey MG, ed. Detection and quantification of antibodies to biopharmaceuticals: practical and applied considerations. Hoboken, NJ: John Wiley and Sons, Inc. pp 3-12.
39. Koren E, Smith HW, Shores E, Shankar G, Finco-Kent D, Rup B, Barret Y-C, Devanarayan V, Gorovits B, Gupta S, Parish T, Quarmby V, Moxness M, Swanson SJ, Taniguchi G, Zuckerman LA, Stebbins CC, Mire-Sluis A. 2008. Recommendations on risk-based strategies for detection and characterization of antibodies against biotechnology products. J Immunol Methods 333:1-9.
40. Krystexxa (pegloticase) injection for intravenous injection: U.S. Prescribing Information. 2010. East Brunswick, NJ: Savient Pharmaceuticals, Inc.
41. Kuter DJ. 2009. Thrombopoietin and thrombopoieting mimetics in the treatment of thrombocytopenia. Annu Rev Med 60: 193-206.
42. Lenhard T, Biller A, Mueller W, Metz I, Schonberger J, Wildemann B. 2010. Immune reconstitution inflammatory syndrome after withdrawal of natalizumab? Neurology 75:831-833.
43. Li J, Yang C, Xia Y, Bertino A, Glaspy J, Roberts M, Kuter DJ. 2001. Thrombocytopenia caused by the development of antibodies to thrombopoietin. Blood 98:3241-3248.
44. Liu W, Swift R, Torraca G, Nashed-Samuel Y, Wen ZQ, Jiang Y, Vance A, Mire-Sluis A, Freund E, Davis J, Narhi L. 2010. Root cause analysis of tungsten-induced protein aggregation in prefilled syringes. PDA J Pharm Sci Technol 64:11-19.
45. Lyseng-Williamson KA. 2011. Pegloticase in treatment-refractory chronic gout. Drugs 71:2179-2192.
46. Maini RN, Breedveld FC, Kalden JR, Smolen JS, Davis D, Macfarlane JD, Antoni C, Leeb B, Elliott MJ, Woody JN, Schaible TF, Feldmann M. 1998. Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis. Arthritis Rheum 41:1552-1563.
47. Markovic I. 2007. Evaluation of safety and quality impact of extractable and leachable substances in therapeutic biologic protein products: a risk-based perspective. Expert Opin Drug Saf 6:487-491.
48. Mire-Sluis AR, Barrett YC, Devanarayan V, Koren E, Liu H, Maia M, Parish T, Scott G, Shankar G, Shores E, Swanson SJ, Taniguchi G, Wierda D, Zuckerman LA. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J Immunol Methods 289:1-16.
49. Moore WV, Leppert P. 1980. Role of aggregated human growth hormone (hGH) in development of antibodies to hGH. J Clin Endocrinol Metab 51:691-697.
50. OP-1 Putty: U.S. Prescribing Information. 2012. Hopkinton, MA: Olympus Biotech Corporation. Literature No. V260241 Rev 01.
51. Patient Protection and Affordable Care Act. 2009. Public Law 111-148 sections 7001-7003.
52. Ponce E, Moskovitz J, Grabowski G. 1997. Enzyme therapy in Gaucher disease type I: effect of neutralizing antibodies to acid-glucosidase. Blood 90:43-48.
53. Pozzilli C, Antonini G, Bagnato F, Mainero C, Tomassini V, Onesti E, Fantozzi R, Galgani S, Pasqualetti P, Millefiorini E, Spadaro M, Dahlke F, Gasperini C. 2002. Monthly corticosteroids decrease neutralizing antibodies to IFNb-1b: a randomized trial in multiple sclerosis. J Neurol 249:50-56.
54. Pringle PH, Hindmarsh PC, Di Silvio L, Teale JD, Kurtz AB, Brook CG. 1989. The measurement and effect of growth hormone in the presence of growth hormone-binding antibodies. J Endocrinol 121:193-199.
55. Rosenberg AS. 2003. Immunogenicity of biological therapeutics: a hierarchy of concerns. Dev Biol (Basel) 112:15-21.
56. Rosenberg AS. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J 8:E501-E507.
57. Rosenberg AS, Verthelyi D, Cherney BW. 2012. Managing uncertainty: a perspective on risk pertaining to the product quality attributes as they bear on immunogenicity of therapeutic proteins. J Pharm Sci 101:3560-3567.
58. Rosenberg AS, Worobec AS. 2004. A risk-based approach to immunogenicity concerns of therapeutic protein products, Part 2: Considering host-specific and product-specific factors impacting immunogenicity. BioPharm Int 1:34-40.
59. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM. 1999. Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93:2081-2088.
60. Rossert J, Casadevall N, Eckardt K-U. 2004. Anti-erythropoietin antibodies and pure red cell aplasia. J Am Soc Nephrol 15:398-406.
61. Schernthaner G. 1993. Immunogenicity and allergenic potential of animal and human insulins. Diabetes Care 16 (Suppl 3):155-165.
62. Schernthaner G, Borkenstein M, Fink M, Mayr WR, Menzel J, Schober E. 1983. Immunogenicity of human insulin (Novo) or pork monocomponent insulin in HLA-DR-typed insulin-dependent diabetic individuals. Diabetes Care 6 (Suppl 1):43-48.
63. Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, Fiscella M, Gorovits B, Kirshner S, Moxness M, Parish T, Quarmby V, Smith H, Smith W, Zuckerman LA, Koren E. 2008. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal 48:1267-1281.
64. Shankar G, Pendley C, Stein KE. 2007. A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugs. Nature Biotech 25:555-561.
65. Sharma B. 2007. Immunogenicity of therapeutic proteins. Part 2: Impact of container closure. Biotechnol Adv 25:318-324.
66. Shin SK, Moon SJ, Ha SK, Jo YI, Lee T-W, Lee Y-S, Kim Y-W, Kim D-J, Kim J-K, Yoo T-H, Lee K-B, Choi SO, Kang EW, Lee KW, Kim S-J, Kim SK, Heo T-H. 2012. Immunogenicity of recombinant human erythropoietin in Korea: a two-year cross-sectional study. Biologicals 40:254-261.
67. Siconolfi LB, Seeds NW. 2001. Mice lacking tPA, uPA or plasminogen genes showed delayed functional recovery after sciatic nerve crush. J Neurosci 21:4348-4355.
68. Smith HW, Moxness M, Marsden R. 2011. Summary of confirmation cut point discussions. AAPS J 13:227-229.
69. Sundy JS, Baraf HSB, Yood RA, Edwards NL, Gutierrez-Urena SR, Treadwell EL, Vazquez-Mellado J, White WB, Lipsky PE, Horowitz Z, Huang W, Maroli AN, Waltrip RW, Hamberger SA, Becker MA. 2011. Efficacy and tolerability of pegloticase for the treatment of chronic gout in patients refractory to conventional treatment: two randomized controlled trials. JAMA 306:711-720.
70. Svenningsson A, Dring AM, Fogdell-Hahn A, Jones I, Engdahl E, Lundkvist M, Brannstrom T, Gilthorpe JD. 2013. Fatal neuroinflammation in a case of multiple sclerosis with antinatalizumab antibodies. Neurology 80:965-967.
71. Thirumangalathu R, Krishnan S, Ricci MS, Brems DN, Randolph TW, Carpenter JF. 2009. Silicone oil- and agitation-induced aggregation of a monoclonal antibody in aqueous solution. J Pharm Sci 98:3176-3181.
72. Tovey MG, Lallemand C. 2011. Immunogenicity and other problems associated with the use of biopharmaceuticals. Ther Adv Drug Saf 2:113-128.
73. Tyagi AK, Randolph TW, Dong A, Maloney KM, Hitscherich C Jr, Carpenter JF. 2009. IgG particle formation during filling pump operation: a case study of heterogeneous nucleation on stainless steel nanoparticles. J Pharm Sci 98:94-104.
74. Tysabri (natalizumab) injection: U.S. Prescribing Information. 2012. Cambridge, MA: Biogen Idec, Inc.
75. Van Dyken SJ, Locksley RM. 2007. Altered self-N-glycans trigger innate-mediated autoimmunity. Immunol Cell Biol 85:527-574.
76. Verthelyi D, Wang V. 2010. Trace levels of innate immune response modulating impurities (IIRMIs) synergize to break tolerance to therapeutic proteins. PLoS ONE 5:e15252.
77. Voraxase (glucarpidase) for injection: U.S. Prescribing Information. 2012. West Conshohocken, PA: BTG International, Inc.
78. VPRIV (velaglucerase alfa) for injection: U.S. Prescribing Information. 2010. Cambridge, MA: Shire Human Genetic Therapies, Inc.
79. Wadhwa M, Thorpe R. 2011. Guidance on immunogenicity assessment of biologically derived therapeutic proteins: a European perspective. In: Tovey MG, ed. Detectionand quantification of antibodies to biopharmaceuticals: Practical and applied considerations. Hoboken, NJ: John Wiley and Sons, Inc. pp 37-56.
80. Weigle WO. 1981. Self-nonself recognition by T and B lymphocytes and their roles in autoimmune phenomena. Arthritis Rheum 24:1044-1053.
81. Weinberg WC, Ha L, Kirshner SL, Verthelyi DI. 2010. Regulatory perspective on aggregates as a product quality attribute. Aggregation of therapeutic proteins. Hoboken, NJ: John Wiley and Sons, Inc. pp 435-448.
82. Xiaflex (collagenase clostridium histolyticum) for injection: U.S. Prescribing Information. 2010. Malvern, PA: Auxilium Pharmaceuticals, Inc.